

ASSIGNMENT

Name	Address
KLEIN, Florian	Erkelenzer Str. 8, 50933 Köln, Germany
GIESELMANN, Lutz	Virchowstr. 31, 50935 Köln, Germany

(collectively referred to as “ASSIGNOR”), each having an address as listed above, are each an inventor or owner of one or more inventions described in the following application(s):

Jurisdiction and Application No.	Filing Date (MM/DD/YYYY)	Title
EP 23206661.3	09.06.2023	BROADLY NEUTRALIZING ANTIBODIES TARGETING THE CD4 BINDING SITE ON HIV ENV
EP 23204223.4	17.10.2023	BROADLY NEUTRALIZING ANTIBODIES TARGETING THE CD4 BINDING SITE ON HIV ENV
EP 23178486.9	30.10.2023	BROADLY NEUTRALIZING ANTIBODIES TARGETING THE CD4 BINDING SITE ON HIV ENV
PCT/EP2024/065842	09.06.2024	BROADLY NEUTRALIZING ANTIBODIES TARGETING THE CD4 BINDING SITE ON HIV ENV

(referred to as the “Application(s)”).

UNIVERSITÄT ZU KÖLN (referred to as “ASSIGNEE”), having an address of Albertus-Magnus-Platz, 50923 Köln, Germany is desirous of acquiring ASSIGNOR’s entire right, title, and interest in and to the one or more inventions, the Application(s), and any letters patent which may be granted for the Application(s) and for any application claiming priority to any of the Application(s) in the United States and in any and all foreign jurisdictions.

In exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR hereby sells, assigns, and transfers, or confirms the previous sale, assignment, and transfer, by law, agreement, or otherwise, to ASSIGNEE, ASSIGNOR’s

entire right, title, and interest in and to the one or more inventions, the Application(s), and any letters patent that may be granted for the Application(s), and for any application claiming priority to any of the Application(s) in the United States and all foreign jurisdictions, including any extensions or adjustments in term thereof, including divisions, continuations, continuations-in-part, reissues thereof, and all post-grant proceedings including but not limited to post-grant review, ex parte reexamination and inter partes review, including the right to file applications directly in the name of ASSIGNEE and to claim priority to any of the Application(s) and any application claiming priority to any of the Application(s) in the United States and in all foreign jurisdictions under any applicable legislation, convention, treaty, or otherwise, and further including the right to sue and obtain legal and equitable relief, including damages, profits, and injunctions, for past, present, and future infringement of any letters patent that may be granted for the Application(s) and for any application claiming priority to any of the Application(s); the Application(s), any application claiming priority to any of the Application(s), and any letters patent that may be granted for the Application(s) or for any application claiming priority to any of the Application(s) to be held and enjoyed by ASSIGNEE and their successors and assigns for their use and benefit as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had the sale, assignment, and transfer not been executed.

ASSIGNOR hereby authorizes the relevant authority to issue all letters patent on the Application(s) and any application claiming priority to any of the Application(s) to ASSIGNEE.

ASSIGNOR agrees to execute all instruments required for the filing and prosecution of the Application(s) and any application claiming priority to any of the Application(s), for litigation regarding any letters patent, or for the purpose of protecting title to the Application(s), or any application claiming priority to any of the Application(s), and any and all letters patent granted therefor. In the event the present Assignment is determined to be ineffective with respect to any portion of ASSIGNOR's right, title, and interest in and to the Application(s) or any application claiming priority to any of the Application(s), ASSIGNOR agrees to assign ASSIGNOR's entire right, title, and interest in and to the Application(s) and any application claiming priority to any of the Application(s) to ASSIGNEE.


ASSIGNOR warrants and agrees that:

- no assignment, sale, agreement, or encumbrance has been or will be made or entered into which would conflict with this assignment;

- upon request, ASSIGNOR will promptly provide ASSIGNEE with all pertinent facts and documents relating to the invention as may be known and accessible to ASSIGNOR;
- ASSIGNOR will, at ASSIGNEE'S expense, testify as to the same in any interference, litigation, or proceeding related to the invention;
- ASSIGNOR will promptly execute and deliver to ASSIGNEE, its assigns or its legal representatives, without further or additional consideration, any and all papers, instruments or affidavits required, render all necessary assistance, and do such additional acts as ASSIGNEE or its successors or assigns may deem necessary or desirable, to apply for, obtain, maintain, issue, and enforce any resulting patents or patent applications; and
- ASSIGNOR hereby waives all rights to challenge validity of said invention, and any and all patents covering the invention that may issue in the future in the United States.

ASSIGNOR hereby authorizes Fox Rothschild LLP to insert the jurisdiction(s), application number(s), filing date(s), patent number(s), issue date(s), and title(s) of the Application(s) and any application claiming priority to any of the Application(s) above.

Date: 31/10/25



Florian KLEIN

(ASSIGNOR)

Date: 31. 10. 2025

 (ASSIGNOR)
Lutz GIESELMANN

UNIVERSITÄTSKLINIKUM KÖLN (AöR)
Der Kaufmännische Direktor
im Auftrag

Abteilungsleitung
Drittmittel

UNIVERSITÄT ZU KÖLN

Beate Becker

Date: 18.11.2025



Signature

(ASSIGNEE)

Printed Name, Title